Compare NOTV & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOTV | CING |
|---|---|---|
| Founded | 1974 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 26.8M |
| IPO Year | 1997 | 2021 |
| Metric | NOTV | CING |
|---|---|---|
| Price | $0.54 | $4.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 534.8K | 133.7K |
| Earning Date | 02-04-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $513,024,000.00 | N/A |
| Revenue This Year | $6.49 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.54 | N/A |
| 52 Week Low | $0.47 | $3.20 |
| 52 Week High | $5.67 | $6.01 |
| Indicator | NOTV | CING |
|---|---|---|
| Relative Strength Index (RSI) | 33.49 | 61.11 |
| Support Level | $0.52 | $3.85 |
| Resistance Level | $0.60 | $4.40 |
| Average True Range (ATR) | 0.05 | 0.26 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 34.16 | 80.60 |
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.